Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
10.1097/CM9.0000000000002873
- VernacularTitle:Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
- Author:
Chen YU
1
;
Songmei GENG
;
Bin YANG
;
Yunhua DENG
;
Fuqiu LI
;
Xiaojing KANG
;
Mingye BI
;
Furen ZHANG
;
Yi ZHAO
;
Weili PAN
;
Zhongwei TIAN
;
Jinhua XU
;
Zhenghua ZHANG
;
Nan YU
;
Xinsuo DUAN
;
Shuping GUO
;
Qing SUN
;
Weiquan LI
;
Juan TAO
;
Zhijun LIU
;
Yuanyuan YIN
;
Gang WANG
Author Information
1. Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
- Keywords:
Tildrakizumab;
Interleukin 23;
Plaque psoriasis;
Chinese;
Randomized controlled trial
- From:
Chinese Medical Journal
2024;137(10):1190-1198
- CountryChina
- Language:Chinese
-
Abstract:
Background::There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients.Methods::In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12.Results::At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73/110] vs. 12.7% [14/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13]; P <0.001) and Physician’s Global Assessment (60.9% [67/110] vs. 10.0% [11/110]; difference, 49.1% [95% CI, 38.64, 59.62]; P <0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks (86.8% [92/106] vs. 82.4% [89/108]) and maintained up to 52 weeks (91.3% [95/104] vs. 87.4% [90/103]). Most treatment-emergent adverse events were mild and not related to tildrakizumab. Conclusion::Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.Trial registration::ClinicalTrials.gov, NCT05108766.
